“Our big push will be to recover that share over the course of the year in the US toxin space.”

In context

“rom where we were. Now we still have to gain some more share over the course of the year to come back to where we were pre the change to Alley. So we have lost year-over-year some share in toxins. In the US in filler, our share is very, very stable. We did not see a significant share impact on the filler side of the business. It's just been sort of a double digit market pressure there. Now in China, I'm quite pleased with the share performance. We've recently had a couple of significant approvals sequentially. We have the masseter approval for BOTOX, which is sort of in the lower face and jawline and also VOLUX, which is in Juvederm. So we've actually seen significant positive momentum in BOTOX share in China as well as positive share in filler. So it's a little variable across the board. Our big push will be to recover that share over the course of the year in the US toxin space. Hope that helps. Operator: Next, we'll go to the line of Alexandria Hammond from Wolfe Research. Alexandria Hammond: So Skyrizi and Rinvoq have consistently surpassed expectations, but we've been getting some questions on what might drive long term growth in I&I as it relates to these assets. Could you comment on when we should start seeing results from your Skyrizi and Rinvoq combination trials? And as a follow-up, what combination are you most excited about from a mechanistic perspective? Roopal Thakkar: I'll start on the Skyrizi question and the combinations. So the studies have initiated and we would anticipate next year starting to see early data readouts. And I would say we're excited about several of these mechanisms. We've utilized quite a bit of data that we've already collected”